Post-marketing Surveillance
Post-marketing Surveillance - Related Videos
05:19
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
0 Views •
2025
Overtreatment is often administered to patients with low-risk prostate cancer; super-active surveillance can help avoid such overtreatment.
01:26
Principles of Disease Surveillance
0 Views •
2025
Disease surveillance is the systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice. This process integrates data dissemination to entities responsible for preventing and controlling disease, injury, and disability. Surveillance systems provide crucial information for action, helping public health authorities make informed decisions to manage and prevent outbreaks, ensure public safety, optimize...
01:27
Immune Surveillance by NK Cells and Phagocytes
0 Views •
2026
Immune surveillance is an integral part of the innate immune system, involving the continuous monitoring of peripheral tissues to detect and respond to pathogens, infected cells, or cancerous cells. This surveillance is conducted primarily by natural killer (NK) cells and phagocytes, which employ distinct but complementary mechanisms to identify and eliminate threats. Natural Killer Cells: The Fast Responders NK cells are large granular lymphocytes found in the blood and lymphatic system. These...
12:09
Avian Influenza Surveillance with FTA Cards: Field Methods, Biosafety, and Transportation Issues Solved
0 Views •
Cited by 42 •
2011
A method to preserve, detect and sequence RNA from Avian Influenza Viruses was validated and extended using natural faecal samples from birds. This technique removes the necessity of maintaining a cool chain and handling of infectious viruses and can be applied in a 96-well high-throughput setup.
08:58
Enhanced Rabies Surveillance Using a Direct Rapid Immunohistochemical Test
0 Views •
Cited by 21 •
2019
The direct rapid immunohistochemical test (DRIT) offers a World Organization for Animal Health and World Health Organization (OIE/WHO) recognized alternative to the direct fluorescent antibody (DFA) test for rabies diagnosis. This test allows for field-based applications that can be performed in approximately 1 h upon brain impressions using light microscopy.
FAQs
Signal detection searches post-marketing data for adverse-event patterns that appear unusual or warrant further assessment. Researchers compare observed patterns with expected background events and examine whether the finding persists across relevant data sources or analyses. This process does not establish causation by itself, but it helps prioritize safety concerns for deeper evaluation and possible regulatory action.
Spontaneous reports do not capture every adverse event, and reporting patterns can vary across products, populations, and time periods. Statistical analyses therefore interpret report counts cautiously rather than treating them as complete measures of occurrence. Disproportionality analysis can highlight events reported more often than expected within the available data, helping identify signals despite limitations in reporting completeness.
Comparing outcomes in exposed and unexposed populations can reveal differences associated with medical-product use, but those groups may also differ in other ways. Confounding occurs when such underlying differences influence the outcome and obscure the product’s contribution. Accounting for confounding makes estimated associations more informative and supports a more careful assessment of benefits and risks.
These sources contribute different kinds of evidence to safety evaluation. Spontaneous reports can reveal suspected adverse-event patterns, while electronic health records and registries support analysis of outcomes in documented patient populations. Combining them broadens surveillance beyond any single source and helps researchers examine adverse-event patterns, incidence, and comparisons across diverse real-world populations.
A typical investigation begins by assembling relevant real-world data, then examining adverse-event patterns through signal detection or disproportionality analysis. Researchers may estimate incidence and compare outcomes between exposed and unexposed populations while considering incomplete reporting and confounding. Findings are then assessed to determine whether they support further safety action, such as risk-management changes or label updates.
Analyses can provide evidence for regulatory decisions, product-label updates, and risk-management strategies after routine use begins. They also support continued evaluation of whether a product’s benefits outweigh its risks across diverse patient populations. By measuring patterns and comparing outcomes in real-world settings, statistical surveillance extends safety assessment beyond the conditions represented in preapproval studies.